Navigation Links
NeurogesX Reports Third Quarter 2009 Results
Date:11/6/2009

ng on November 16, 2009 by dialing 1-877-660-6853 (USA) or 1-201-612-7415 (International), Account Number: 3055, Conference ID Number: 336156. A replay of the webcast will also be available on the corporate website for one month, through December 6, 2009.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza(TM), a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the treatment of neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. Qutenza will be marketed in the European Union, Switzerland, Norway, Iceland, Liechtenstein and certain countries in Eastern Europe, the Middle East and Africa, by Astellas Pharma Europe, Ltd. In the United States, NeurogesX submitted a new drug application (NDA) for PHN to the U.S. Food and Drug Administration (FDA) which was accepted for filing by the FDA in December 2008 and has been given an extended Prescription Drug User Fee Act (PDUFA) date of November 16, 2009.

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently planning the design and timing of this program.

NeurogesX' early stage product pipeline includes pre-clinic
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NeurogesX to Present at Two November Conferences
2. NeurogesX to Present at UBS Global Life Sciences Conference
3. NeurogesX to Present at Upcoming Fall Conferences
4. NeurogesX Appoints New Board Director and Audit Committee Chairman
5. NeurogesX Reports Second Quarter 2009 Results
6. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
7. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
8. NeurogesX Added to Russell 3000 Index
9. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
10. NeurogesX to Present at Needham Life Sciences Conference
11. NeurogesX Receives European Commission Approval for Qutenza(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... August 22, 2014 Nerium International, ... is in the spotlight again. Nerium will showcase ... its NeriumFirmTM Body Contouring Cream to Hollywood’s elite ... Creations during the 66th Primetime Emmy® Awards. , ... extract, third-party clinical trials show that NeriumAD night ...
(Date:8/21/2014)... 2014 DNA vaccine pioneer Immunomic ... development of JRC-LAMP-vax, an innovative and safe potential treatment ... studies began this month in Hawaii, moving the world ... The Japanese red cedar releases pollen that causes devastating ... Cedar pollen wreaks similar havoc in Colorado, New Mexico ...
(Date:8/21/2014)... , August 21, 2014 ... http://www.researchandmarkets.com/research/3zh3q8/global_hormone ) has announced the addition of ...  report to their offering.       ... as hormone therapy, is a means of ... produced by the body. This type of ...
(Date:8/21/2014)... , Aug. 21, 2014  Decision Resources Group ... Brazil and Mexico ... of several newly approved agents, the anticipated label ... and the launch of emerging biologics will substantially ... particular, the emerging IL-5 inhibitors will introduce a ...
Breaking Biology Technology:Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3
... neuromodulation products designed to accelerate recovery from central nervous system ... of inpatient rehabilitative healthcare services, will expand the availability of ... Foot Drop System to 88 rehabilitation hospitals nationwide. ... ...
... ON ALS CLINICALS AND DRUG DEVELOPMENT, ROCKVILLE, ... (Amex: CUR ) announced that Dr. Thomas ... President, Research. He will be,working with Dr. Karl ... the company,s upcoming clinical trial for ALS,(Amytrophic Lateral ...
... Proceeds to Advance Clinical Development Of Lead Drug ... Cytochroma today announced the,closing of a CDN $45 ... by a,new investor, Mitsubishi Tanabe Pharma Corporation ("MTPC"), ... Vengrowth Advanced Life,Sciences Fund Inc., Caisse de Depot ...
Cached Biology Technology: Bioness Announces NESS H200 and L300 Systems to Be Available at 88 HealthSouth Hospitals Nationwide 2 Bioness Announces NESS H200 and L300 Systems to Be Available at 88 HealthSouth Hospitals Nationwide 3Neuralstem Fills Key Product Development Position 2Cytochroma Closes $45 Million Series C Financing 2Cytochroma Closes $45 Million Series C Financing 3
(Date:8/21/2014)... dandruff, eczema and other itchy, flaky maladies in humans ... Hawaiian coral reefs and the extreme environments of arctic ... the scientific journal PLOS Pathogens considers the ... genus Malassezia in light of new insights ... world. , University of Hawai,i at Mānoa scientist Anthony ...
(Date:8/21/2014)... improving the food intake, health and quality of life ... three projects at the University of Waterloo receiving close ... of Health Research (CIHR). , Professor Heather Keller, ... and a Schlegel research chair in nutrition and aging, ... many Canadians living in long-term care homes are poorly ...
(Date:8/21/2014)... a finding that has implications for life in other ... the solar system, LSU Associate Professor of Biological Sciences ... Science Foundation, or NSF, this week published a paper ... that lies 800 meters (2600 feet) beneath the surface ... ecosystems.", Given that more than 400 subglacial lakes and ...
Breaking Biology News(10 mins):From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2Grants will fund landmark aging research at Waterloo 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 3800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 4
... train passenger, a molecule called oskar RNA carries a ... scientists at the European Molecular Biology Laboratory (EMBL) in ... molecule, moving in the right direction isn,t enough: speed ... in Nature Structural & Molecular Biology , also ...
... A paper published online today in Nature ... to replace faulty immune system cells in models of ... the childhood disorder, including abnormal breathing and movement, and ... the function of microglia deficient in methyl-CpG binding protein ...
... no surprise that giant and colossal squid are big, but ... comes to size, with diameters measuring two or three times ... March 15 in Current Biology , a Cell Press ... Giant squids, 10-inch eyes allow them to see very large ...
Cached Biology News:Need for speed 2Bone marrow transplant arrests symptoms in model of Rett syndrome 2Bone marrow transplant arrests symptoms in model of Rett syndrome 3Giant squids' giant eyes: The better to see hungry whales with 2
Integrins Sampler Kit 10g each...
Protein Tyrosine Phosphatase Sampler Kit 10g each...
... reagent for Virus isolation ... unique water insoluble Elastomeric ... and chaotropes; Engineered to ... viruses while preserving infectivity; ...
Caveolin Sampler Kit 10g each...
Biology Products: